VIR
NASDAQ · Biotechnology
Vir Biotechnology Inc
$9.16
-0.14 (-1.51%)
Financial Highlights (FY 2026)
Revenue
88.80M
Net Income
-567,324,917
Gross Margin
100.0%
Profit Margin
-638.9%
Rev Growth
-65.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 41.4% | 41.4% |
| Operating Margin | -699.2% | -629.3% | -31.7% | -35.1% |
| Profit Margin | -638.9% | -606.9% | -27.2% | -30.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 88.80M | 254.58M | 113.39M | 105.81M |
| Gross Profit | 88.76M | 254.48M | 46.97M | 43.83M |
| Operating Income | -620,854,989 | -1,601,976,749 | -35,981,507 | -37,098,247 |
| Net Income | -567,324,917 | -1,463,854,430 | -30,823,495 | -32,439,743 |
| Gross Margin | 100.0% | 100.0% | 41.4% | 41.4% |
| Operating Margin | -699.2% | -629.3% | -31.7% | -35.1% |
| Profit Margin | -638.9% | -606.9% | -27.2% | -30.7% |
| Rev Growth | -65.1% | -65.1% | +24.3% | +5.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 432.19M | 355.41M |
| Total Equity | — | — | 459.65M | 428.15M |
| D/E Ratio | — | — | 0.94 | 0.83 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -620,363,041 | -1,689,635,576 | -42,153,177 | -39,538,454 |
| Free Cash Flow | — | — | -22,930,380 | -17,215,226 |